3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Ovarian Neoplasms
21
Breast Neoplasms
11
Prostatic Neoplasms
10
Fallopian Tube Neoplasms
8
Neoplasms
7
Neoplasm Metastasis
7
Pancreatic Neoplasms
6
Endometrial Neoplasms
5
Triple Negative Breast Neoplasms
4
Lung Neoplasms
3
Head and Neck Neoplasms
3
Glioblastoma
3
Carcinoma, Ovarian Epithelial
3
Small Cell Lung Carcinoma
2
Prostatic Neoplasms, Castration-Resistant
2
Glioma
2
Carcinoma, Non-Small-Cell Lung
2
Brain Neoplasms
2
Biliary Tract Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urinary Bladder Neoplasms
1
Unilateral Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
SCLC,Extensive Stage
1
Recurrence
1
Rectal Neoplasms
1
Prostate Adenocarcinoma
1
Interventions
Gemcitabine
5
Taxes
3
Albumin-Bound Paclitaxel
3
Radiotherapy, Intensity-Modulated
2
Radiotherapy
2
Oxaliplatin
2
Losartan
2
Leucovorin
2
Irinotecan
2
Fluorouracil
2
130-nm albumin-bound paclitaxel
2
tocilizumab
1
selicrelumab
1
niraparib
1
durvalumab
1
dehydroftorafur
1
cobimetinib
1
atezolizumab
1
X-Rays
1
Tiragolumab
1
Standard of Care
1
Specimen Handling
1
Radiation
1
Panitumumab
1
Pancreaticoduodenectomy
1
PEGPH20
1
Optical Imaging
1
Nivolumab
1
Metformin
1
Ipilimumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Adenocarcinoma
×
niraparib
×
1 year
×
Clear all
NCT03404960
2025-10-10
Parpvax
University of Pennsylvania
Phase 1/2
Completed
104 enrolled
11 charts